PMID- 34368124
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210810
IS  - 2296-634X (Print)
IS  - 2296-634X (Electronic)
IS  - 2296-634X (Linking)
VI  - 9
DP  - 2021
TI  - Identification of a Novel Immune Landscape Signature for Predicting Prognosis and 
      Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy.
PG  - 671736
LID - 10.3389/fcell.2021.671736 [doi]
LID - 671736
AB  - Uterine Corpus Endometrial Carcinoma (UCEC) is the most common gynecological 
      cancer. Here, we have investigated the significance of immune-related genes in 
      predicting the prognosis and response of UCEC patients to immunotherapy and 
      chemotherapy. Based on the Cancer Genome Atlas (TCGA) database, the single-sample 
      gene-set enrichment analysis (ssGSEA) scores was utilized to obtain enrichment of 
      29 immune signatures. Univariate, multivariate Cox regression and least absolute 
      shrinkage and selection operator (LASSO) regression analyses were performed to 
      generate an immune-related prognostic signature (IRPS). The biological functions 
      of IRPS-associated genes were evaluated using GSEA, Tumor Immune Estimation 
      Resource (TIMER) Database analysis, Mutation analysis, Immunophenoscore (IPS) 
      analysis, Gene Expression Profiling Interactive Analysis (GEPIA), Genomics of 
      Drug Sensitivity in Cancer (GDSC) and Immune Cell Abundance Identifier 
      (ImmuCellAI). Potential small molecule drugs for UCEC were predicted using the 
      connectivity map (Cmap). The mRNA and protein expression levels of 
      IRPS-associated genes were tested via quantitative real-time PCR (qPCR) and 
      immunohistology. Two immune-related genes (CCL13 and KLRC1) were identified to 
      construct the IRPS. Both genes were related to the prognosis of UCEC patients (P 
      < 0.05). The IRPS could distinguish patients with different prognosis and was 
      closely associated with the infiltration of several types of immune cells. Our 
      findings showed that patients with low IRPS benefited more from immunotherapy and 
      developed stronger response to several chemotherapies, which was also confirmed 
      by the results of ImmuCellAI. Finally, we identified three small molecular drugs 
      that might improve the prognosis of patients with high IRPS. IRPS can be utilized 
      to predict the prognosis of UCEC patients and provide valuable information about 
      their therapeutic response to immunotherapy and chemotherapy.
CI  - Copyright (c) 2021 Liu, Wang, Mei, Nie and Zhang.
FAU - Liu, Jinhui
AU  - Liu J
AD  - Department of Gynecology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Wang, Yichun
AU  - Wang Y
AD  - Department of Urology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Mei, Jie
AU  - Mei J
AD  - Department of Gynecology and Obstetrics, Wuxi Maternal and Child Health Hospital, 
      The Affiliated Hospital to Nanjing Medical University, Wuxi, China.
AD  - Wuxi Clinical Medical College, Nanjing Medical University, Wuxi, China.
FAU - Nie, Sipei
AU  - Nie S
AD  - Department of Gynecology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Department of Gynecology and Obstetrics, Wuxi Maternal and Child Health Hospital, 
      The Affiliated Hospital to Nanjing Medical University, Wuxi, China.
LA  - eng
PT  - Journal Article
DEP - 20210723
PL  - Switzerland
TA  - Front Cell Dev Biol
JT  - Frontiers in cell and developmental biology
JID - 101630250
PMC - PMC8343236
OTO - NOTNLM
OT  - chemotherapy
OT  - endometrial carcinoma
OT  - immunotherapy
OT  - prognosis
OT  - tumor immune microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/08/10 06:00
MHDA- 2021/08/10 06:01
PMCR- 2021/01/01
CRDT- 2021/08/09 06:41
PHST- 2021/02/24 00:00 [received]
PHST- 2021/07/01 00:00 [accepted]
PHST- 2021/08/09 06:41 [entrez]
PHST- 2021/08/10 06:00 [pubmed]
PHST- 2021/08/10 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fcell.2021.671736 [doi]
PST - epublish
SO  - Front Cell Dev Biol. 2021 Jul 23;9:671736. doi: 10.3389/fcell.2021.671736. 
      eCollection 2021.